Ovarian Cancer Drug Shows Promise

Wednesday, 12 Jun 2013 12:01 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink

Amgen Inc said on Wednesday that its trebananib treatment for ovarian cancer had reduced the risk of disease progression or death by 34 percent in a clinical trial.
 
The company said the drug had met its primary goal in the trial, which is the first of three for the new treatment.
 
Amgen said that while it was working on the primary analysis of overall survival for 2014, it saw a favorable survival trend in an interim analysis.
 
Shares in Amgen were up slightly $98.25 in Nasdaq morning trading.

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Lung Cancer Drug Shows Effectiveness in Trial

Thursday, 30 Oct 2014 12:21 PM

Treatment of advanced squamous cell non-small cell lung cancer (NSCLC) with Bristol-Myers Squibb Co's experimental immun . . .

Celiac Sufferers Have Higher Bone Fracture Risk

Thursday, 30 Oct 2014 12:18 PM

People diagnosed with celiac disease are almost twice as likely as those without it to break a bone, according to a new  . . .

Whole-Eye Transplants Promise to Cure Blindness

Thursday, 30 Oct 2014 12:12 PM

In the world of 21st-century medicine, organ transplantation is nothing new. The first kidney transplant took place in 1 . . .

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved